Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) FCF Margin (2016 - 2025)

CytomX Therapeutics' FCF Margin history spans 12 years, with the latest figure at 3502.87% for Q4 2025.

  • For Q4 2025, FCF Margin fell 345119.0% year-over-year to 3502.87%; the TTM value through Dec 2025 reached 99.19%, down 3675.0%, while the annual FY2025 figure was 99.19%, 3675.0% down from the prior year.
  • FCF Margin reached 3502.87% in Q4 2025 per CTMX's latest filing, down from 258.61% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 39.58% in Q1 2023 to a low of 3502.87% in Q4 2025.
  • Average FCF Margin over 5 years is 335.72%, with a median of 94.57% recorded in 2023.
  • Peak YoY movement for FCF Margin: surged 50472bps in 2023, then plummeted -345119bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 282.4% in 2021, then skyrocketed by 97bps to 7.83% in 2022, then crashed by -931bps to 80.67% in 2023, then surged by 36bps to 51.68% in 2024, then tumbled by -6678bps to 3502.87% in 2025.
  • Per Business Quant, the three most recent readings for CTMX's FCF Margin are 3502.87% (Q4 2025), 258.61% (Q3 2025), and 85.21% (Q2 2025).